| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:52:03 UTC |
|---|
| HMDB ID | HMDB0015636 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Agomelatine |
|---|
| Description | Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name. |
|---|
| Structure | COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1 InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17) |
|---|
| Synonyms | | Value | Source |
|---|
| Valdoxan | Kegg | | S-20098 | HMDB | | S20098 | HMDB | | N-(2-(7-Methoxy-1-naphthyl)ethyl)acetamide | HMDB | | Thymanax | HMDB | | Ago 178 | HMDB | | Ago-178 | HMDB |
|
|---|
| Chemical Formula | C15H17NO2 |
|---|
| Average Molecular Weight | 243.301 |
|---|
| Monoisotopic Molecular Weight | 243.125928793 |
|---|
| IUPAC Name | N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide |
|---|
| Traditional Name | agomelatine |
|---|
| CAS Registry Number | 138112-76-2 |
|---|
| SMILES | COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1 |
|---|
| InChI Identifier | InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17) |
|---|
| InChI Key | YJYPHIXNFHFHND-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as n-acetyl-2-arylethylamines. N-acetyl-2-arylethylamines are compounds containing an acetamide group that is N-linked to an arylethylamine. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Carboxylic acid derivatives |
|---|
| Direct Parent | N-acetyl-2-arylethylamines |
|---|
| Alternative Parents | |
|---|
| Substituents | - N-acetyl-2-arylethylamine
- Naphthalene
- Anisole
- Alkyl aryl ether
- Benzenoid
- Secondary carboxylic acid amide
- Ether
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic nitrogen compound
- Carbonyl group
- Organic oxygen compound
- Hydrocarbon derivative
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0078 g/L | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 156.3 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.71 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.308 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.73 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 25.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1770.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 364.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 176.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 202.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 113.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 553.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 595.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 86.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 972.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 519.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1453.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 320.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 378.9 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 317.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 194.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Agomelatine,1TMS,isomer #1 | COC1=CC=C2C=CC=C(CCN(C(C)=O)[Si](C)(C)C)C2=C1 | 2210.6 | Semi standard non polar | 33892256 | | Agomelatine,1TMS,isomer #1 | COC1=CC=C2C=CC=C(CCN(C(C)=O)[Si](C)(C)C)C2=C1 | 2477.3 | Standard non polar | 33892256 | | Agomelatine,1TMS,isomer #1 | COC1=CC=C2C=CC=C(CCN(C(C)=O)[Si](C)(C)C)C2=C1 | 2924.4 | Standard polar | 33892256 | | Agomelatine,1TBDMS,isomer #1 | COC1=CC=C2C=CC=C(CCN(C(C)=O)[Si](C)(C)C(C)(C)C)C2=C1 | 2417.0 | Semi standard non polar | 33892256 | | Agomelatine,1TBDMS,isomer #1 | COC1=CC=C2C=CC=C(CCN(C(C)=O)[Si](C)(C)C(C)(C)C)C2=C1 | 2670.0 | Standard non polar | 33892256 | | Agomelatine,1TBDMS,isomer #1 | COC1=CC=C2C=CC=C(CCN(C(C)=O)[Si](C)(C)C(C)(C)C)C2=C1 | 2987.6 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Agomelatine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0096-9870000000-12644f5c2eef8ac161ff | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Agomelatine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Agomelatine , positive-QTOF | splash10-000i-1910000000-17cebfbe6b9845617b5d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 10V, Positive-QTOF | splash10-0udl-0290000000-2f32e7333df35f0d31e0 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 20V, Positive-QTOF | splash10-0udi-1890000000-f8670d6acc856a2aef34 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 40V, Positive-QTOF | splash10-103c-1900000000-44f5e0bbe33a080e259b | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 10V, Negative-QTOF | splash10-0006-1190000000-60e7560fd8d53fc46465 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 20V, Negative-QTOF | splash10-0zfu-3590000000-b1f2b056df1b588a9894 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 40V, Negative-QTOF | splash10-052f-9200000000-7d7eb2751fc51b48fda4 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 10V, Positive-QTOF | splash10-000l-0960000000-1b1a339607ebe3d5742f | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 20V, Positive-QTOF | splash10-000i-0900000000-84ce72fe2cc1bb7fae00 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 40V, Positive-QTOF | splash10-0a4i-1900000000-0471137531ade7533965 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 10V, Negative-QTOF | splash10-00di-0910000000-64f66595ca495c9bd240 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 20V, Negative-QTOF | splash10-0a4i-1900000000-5cf1d78282a06e7b1962 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Agomelatine 40V, Negative-QTOF | splash10-0a4l-5900000000-9ed4ac12ad0427b40af3 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999 ]
- Racagni G, Riva MA, Popoli M: The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007 Oct;22 Suppl 2:S9-S14. [PubMed:17917564 ]
- Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP: Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. doi: 10.1055/s-0031-1296459. [PubMed:18368944 ]
|
|---|